Reviewing Pheton Holdings Ltd Class A Ordinary Shares (NASDAQ:PTHL) and Electromed (NYSE:ELMD)

Electromed (NYSE:ELMD) and Pheton Holdings Ltd Class A Ordinary Shares (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Profitability

This table compares Electromed and Pheton Holdings Ltd Class A Ordinary Shares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Pheton Holdings Ltd Class A Ordinary Shares	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Electromed and Pheton Holdings Ltd Class A Ordinary Shares, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0	0	0	1	4.00
Pheton Holdings Ltd Class A Ordinary Shares	0	0	0	0	0.00

Electromed presently has a consensus price target of $38.00, suggesting a potential upside of 85.55%. Given Electromed’s stronger consensus rating and higher possible upside, equities analysts plainly believe Electromed is more favorable than Pheton Holdings Ltd Class A Ordinary Shares.

Institutional and Insider Ownership

40.8% of Electromed shares are owned by institutional investors. 14.0% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Electromed and Pheton Holdings Ltd Class A Ordinary Shares”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$61.44 million	2.80	$5.15 million	$0.79	25.92
Pheton Holdings Ltd Class A Ordinary Shares	$448,196.00	88.41	N/A	N/A	N/A

Electromed has higher revenue and earnings than Pheton Holdings Ltd Class A Ordinary Shares.

Summary

Electromed beats Pheton Holdings Ltd Class A Ordinary Shares on 9 of the 10 factors compared between the two stocks.

About Electromed

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

About Pheton Holdings Ltd Class A Ordinary Shares

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.